;PMID: 11211612
;source_file_579.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..40] = [t:0..40]
;1)sentence:[e:45..101] = [t:45..101]
;2)sentence:[e:102..179] = [t:102..179]
;3)section:[e:183..268] = [t:183..268]
;4)section:[e:272..402] = [t:272..402]
;5)sentence:[e:406..547] = [t:406..547]
;6)sentence:[e:548..685] = [t:548..685]
;7)sentence:[e:686..1057] = [t:686..1057]
;8)sentence:[e:1058..1136] = [t:1058..1136]
;9)sentence:[e:1137..1258] = [t:1137..1258]
;10)sentence:[e:1259..1394] = [t:1259..1394]
;11)section:[e:1395..1606] = [t:1395..1606]
;12)section:[e:1610..1655] = [t:1610..1655]

;section 0 Span:0..40
;Am J Clin Pathol  2001 Feb;115(2):235-42
(SEC
  (FRAG (NNP:[0..2] Am) (NNP:[3..4] J) (NNP:[5..9] Clin) (NNP:[10..16] Pathol)
        (CD:[18..22] 2001) (IN:[23..29] Feb;11) (CD:[29..30] 5)
        (NN:[30..31] -LRB-) (CD:[31..32] 2) (NN:[32..33] -RRB-) (::[33..34] :)
        (CD:[34..36] 23) (CD:[36..40] 5-42)))

;sentence 1 Span:45..101
;H-ras oncogene mutation in dedifferentiated liposarcoma.
;[45..50]:gene-rna:"H-ras"
;[72..100]:malignancy:"dedifferentiated liposarcoma"
(SENT
  (NP-HLN
    (NP (NN:[45..50] H-ras) (NN:[51..59] oncogene) (NN:[60..68] mutation))
    (PP (IN:[69..71] in)
      (NP (VBN:[72..88] dedifferentiated) (NN:[89..100] liposarcoma)))
    (.:[100..101] .)))

;sentence 2 Span:102..179
;Polymerase chain  reaction-restriction fragment length polymorphism
;analysis.
;[102..112]:gene-protein:"Polymerase"
(SENT
  (NP
    (NML (NN:[102..112] Polymerase) (NN:[113..118] chain)
         (NN:[120..128] reaction))
    (HYPH:[128..129] -)
    (NML (NN:[129..140] restriction) (NN:[141..149] fragment)
         (NN:[150..156] length) (NN:[157..169] polymorphism))
    (NN:[170..178] analysis) (.:[178..179] .)))

;section 3 Span:183..268
;Sakamoto A, Oda Y, Adachi T, Tamiya S, Matsuda S, Tanaka K, Iwamoto Y, 
;Tsuneyoshi M.
(SEC
  (FRAG (NNP:[183..191] Sakamoto) (NNP:[192..193] A) (,:[193..194] ,)
        (NNP:[195..198] Oda) (NNP:[199..200] Y) (,:[200..201] ,)
        (NNP:[202..208] Adachi) (NNP:[209..210] T) (,:[210..211] ,)
        (NNP:[212..218] Tamiya) (NNP:[219..220] S) (,:[220..221] ,)
        (NNP:[222..229] Matsuda) (NNP:[230..231] S) (,:[231..232] ,)
        (NNP:[233..239] Tanaka) (NNP:[240..242] K,) (NNP:[243..250] Iwamoto)
        (NNP:[251..252] Y) (,:[252..253] ,) (NNP:[255..265] Tsuneyoshi)
        (NNP:[266..268] M.)))

;section 4 Span:272..402
;Departments of Anatomic Pathology, Pathological Sciences, Graduate School of 
;Medical Sciences, Kyushu University, Fukuoka, Japan.
(SEC
  (FRAG (NNP:[272..283] Departments) (IN:[284..286] of)
        (NNP:[287..295] Anatomic) (NNP:[296..305] Pathology) (,:[305..306] ,)
        (NNP:[307..319] Pathological) (NNP:[320..328] Sciences) (,:[328..329] ,)
        (NNP:[330..338] Graduate) (NNP:[339..345] School) (IN:[346..348] of)
        (NNP:[350..357] Medical) (NNPS:[358..366] Sciences) (,:[366..367] ,)
        (NNP:[368..374] Kyushu) (NNP:[375..385] University) (,:[385..386] ,)
        (NNP:[387..394] Fukuoka) (,:[394..395] ,) (NNP:[396..401] Japan)
        (.:[401..402] .)))

;sentence 5 Span:406..547
;Point mutations of the ras gene family (K-ras, H-ras, and N-ras) are thought
;to  be involved in the development of a variety of human tumors.
;[406..421]:variation-type:"Point mutations"
;[429..432]:gene-rna:"ras"
;[446..451]:gene-rna:"K-ras"
;[453..458]:gene-rna:"H-ras"
;[464..469]:gene-rna:"N-ras"
;[540..546]:malignancy:"tumors"
(SENT
  (S
    (NP-SBJ-1
      (NP (NN:[406..411] Point) (NNS:[412..421] mutations))
      (PP (IN:[422..424] of)
        (NP (DT:[425..428] the)
          (NML (NN:[429..432] ras) (NN:[433..437] gene))
          (NN:[438..444] family)
          (PRN (-LRB-:[445..446] -LRB-)
            (NP (NN:[446..451] K-ras) (,:[451..452] ,) (NN:[453..458] H-ras)
                (,:[458..459] ,) (CC:[460..463] and) (NN:[464..469] N-ras))
            (-RRB-:[469..470] -RRB-)))))
    (VP (VBP:[471..474] are)
      (VP (VBN:[475..482] thought)
        (S
          (NP-SBJ-1 (-NONE-:[482..482] *))
          (VP (TO:[483..485] to)
            (VP (VB:[487..489] be)
              (VP (JJ:[490..498] involved)
                (NP-1 (-NONE-:[498..498] *))
                (PP-CLR (IN:[499..501] in)
                  (NP
                    (NP (DT:[502..505] the) (NN:[506..517] development))
                    (PP (IN:[518..520] of)
                      (NP
                        (NP (DT:[521..522] a) (NN:[523..530] variety))
                        (PP (IN:[531..533] of)
                          (NP (JJ:[534..539] human) (NNS:[540..546] tumors)))))))))))))
    (.:[546..547] .)))

;sentence 6 Span:548..685
;Dedifferentiated  liposarcoma is characterized by the coexistence of
;well-differentiated (WD) and  high-grade anaplastic (HG) components.
;[548..577]:malignancy:"Dedifferentiated  liposarcoma"
;[617..636]:malignancy:"well-differentiated"
;[638..640]:malignancy:"WD"
;[647..668]:malignancy:"high-grade anaplastic"
;[670..672]:malignancy:"HG"
(SENT
  (S
    (NP-SBJ-2 (VBN:[548..564] Dedifferentiated) (NN:[566..577] liposarcoma))
    (VP (VBZ:[578..580] is)
      (VP (VBN:[581..594] characterized)
        (NP-2 (-NONE-:[594..594] *))
        (PP (IN:[595..597] by)
          (NP
            (NP (DT:[598..601] the) (NN:[602..613] coexistence))
            (PP (IN:[614..616] of)
              (NP
                (NP
                  (ADJP (RB:[617..621] well) (HYPH:[621..622] -)
                        (VBN:[622..636] differentiated))
                  (PRN (-LRB-:[637..638] -LRB-) (JJ:[638..640] WD)
                       (-RRB-:[640..641] -RRB-))
                  (NML-1 (-NONE-:[641..641] *P*)))
                (CC:[642..645] and)
                (NP
                  (NML
                    (NML (JJ:[647..657] high-grade) (JJ:[658..668] anaplastic))
                    (NML (-LRB-:[669..670] -LRB-) (JJ:[670..672] HG)
                         (-RRB-:[672..673] -RRB-)))
                  (NML-1 (NNS:[674..684] components)))))))))
    (.:[684..685] .)))

;sentence 7 Span:686..1057
;The presence of point mutations at codons  12 and 13 of the H-ras gene was
;studied in 34 liposarcomas, comprising 15  well-differentiated liposarcomas
;and 19 dedifferentiated liposarcomas, and in 8  storiform-pleomorphic type
;malignant fibrous histiocytomas (MFHs) using  polymerase chain
;reaction-restriction fragment length polymorphism and direct  sequencing
;analysis.
;[702..717]:variation-type:"point mutations"
;[721..731]:variation-location:"codons  12"
;[721..727]...[736..738]:variation-location:"codons"..."13"
;[746..751]:gene-rna:"H-ras"
;[775..787]:malignancy:"liposarcomas"
;[804..836]:malignancy:"well-differentiated liposarcomas"
;[844..873]:malignancy:"dedifferentiated liposarcomas"
;[885..943]:malignancy:"storiform-pleomorphic type malignant fibrous
;histiocytomas"
;[945..949]:malignancy:"MFHs"
;[958..968]:gene-protein:"polymerase"
(SENT
  (S
    (NP-SBJ-2
      (NP (DT:[686..689] The) (NN:[690..698] presence))
      (PP (IN:[699..701] of)
        (NP (NN:[702..707] point) (NNS:[708..717] mutations)))
      (PP (IN:[718..720] at)
        (NP
          (NP
            (NP
              (NML-1 (NNS:[721..727] codons))
              (CD:[729..731] 12))
            (CC:[732..735] and)
            (NP
              (NML-1 (-NONE-:[735..735] *P*))
              (CD:[736..738] 13)))
          (PP (IN:[739..741] of)
            (NP (DT:[742..745] the) (NN:[746..751] H-ras) (NN:[752..756] gene))))))
    (VP (VBD:[757..760] was)
      (VP (VBN:[761..768] studied)
        (NP-2 (-NONE-:[768..768] *))
        (PP-LOC
          (PP (IN:[769..771] in)
            (NP
              (NP (CD:[772..774] 34) (NNS:[775..787] liposarcomas))
              (,:[787..788] ,)
              (VP (VBG:[789..799] comprising)
                (NP
                  (NP (CD:[800..802] 15)
                    
                    (ADJP (RB:[804..808] well) (HYPH:[808..809] -)
                          (VBN:[809..823] differentiated))
                    (NNS:[824..836] liposarcomas))
                  (CC:[837..840] and)
                  (NP (CD:[841..843] 19)
                     (VBN:[844..860] dedifferentiated)
                     (NNS:[861..873] liposarcomas))))))
          (,:[873..874] ,) (CC:[875..878] and)
          (PP (IN:[879..881] in)
            (NP (CD:[882..883] 8)
              (NML
                (ADJP (JJ:[885..894] storiform) (HYPH:[894..895] -)
                      (JJ:[895..906] pleomorphic))
                (NN:[907..911] type))
              (NML
                (NML (JJ:[912..921] malignant) (JJ:[922..929] fibrous)
                     (NNS:[930..943] histiocytomas))
                (NML (-LRB-:[944..945] -LRB-) (NNS:[945..949] MFHs)
                     (-RRB-:[949..950] -RRB-))))))
        (S-MNR
          (NP-SBJ (-NONE-:[950..950] *))
          (VP (VBG:[951..956] using)
            (NP
              (NP
                (NML (NN:[958..968] polymerase) (NN:[969..974] chain)
                     (NN:[975..983] reaction))
                (HYPH:[983..984] -)
                (NML (NN:[984..995] restriction) (NN:[996..1004] fragment)
                     (NN:[1005..1011] length) (NN:[1012..1024] polymorphism)))
              (CC:[1025..1028] and)
              (NP (JJ:[1029..1035] direct) (NN:[1037..1047] sequencing)
                  (NN:[1048..1056] analysis)))))))
    (.:[1056..1057] .)))

;sentence 8 Span:1058..1136
;The 2 components of dedifferentiated liposarcoma were  analyzed
;independently.
;[1078..1106]:malignancy:"dedifferentiated liposarcoma"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[1058..1061] The) (CD:[1062..1063] 2)
          (NNS:[1064..1074] components))
      (PP (IN:[1075..1077] of)
        (NP (VBN:[1078..1094] dedifferentiated) (NN:[1095..1106] liposarcoma))))
    (VP (VBD:[1107..1111] were)
      (VP (VBN:[1113..1121] analyzed)
        (NP-1 (-NONE-:[1121..1121] *))
        (ADVP (RB:[1122..1135] independently))))
    (.:[1135..1136] .)))

;sentence 9 Span:1137..1258
;H-ras mutations were seen only in dedifferentiated  liposarcomas (4/19
;[21%]), 1 in WD components and 3 in HG components.
;[1137..1142]:gene-rna:"H-ras"
;[1171..1201]:malignancy:"dedifferentiated  liposarcomas"
;[1221..1234]:malignancy:"WD components"
;[1244..1257]:malignancy:"HG components"
(SENT
  (S
    (NP-SBJ-1 (NN:[1137..1142] H-ras) (NNS:[1143..1152] mutations))
    (VP (VBD:[1153..1157] were)
      (VP (VBN:[1158..1162] seen)
        (NP-1 (-NONE-:[1162..1162] *))
        (ADVP (RB:[1163..1167] only))
        (PP (IN:[1168..1170] in)
          (NP
            (NP
               (VBN:[1171..1187] dedifferentiated)
               (NNS:[1189..1201] liposarcomas)
              (PRN (-LRB-:[1202..1203] -LRB-)
                (NP
                  (NP (CD:[1203..1204] 4))
                  (PP (SYM:[1204..1205] /)
                    (NP (CD:[1205..1207] 19)
                      (PRN (-LRB-:[1208..1209] -LSB-)
                        (NP (CD:[1209..1211] 21) (NN:[1211..1212] %))
                        (-RRB-:[1212..1213] -RSB-)))))
                (-RRB-:[1213..1214] -RRB-)))
            (,:[1214..1215] ,)
            (NP
              (NP
                (NP (CD:[1216..1217] 1))
                (PP (IN:[1218..1220] in)
                  (NP (JJ:[1221..1223] WD) (NNS:[1224..1234] components))))
              (CC:[1235..1238] and)
              (NP
                (NP (CD:[1239..1240] 3))
                (PP (IN:[1241..1243] in)
                  (NP (JJ:[1244..1246] HG) (NNS:[1247..1257] components)))))))))
    (.:[1257..1258] .)))

;sentence 10 Span:1259..1394
;The  mutation was not seen in any of 15 cases of well-differentiated
;liposarcoma.  MFHs showed an H-ras mutation in 1 (12%) of 8 cases.
;[1259..1272]:variation-event:"The  mutation"
;[1308..1339]:malignancy:"well-differentiated liposarcoma"
;[1342..1346]:malignancy:"MFHs"
;[1357..1362]:gene-rna:"H-ras"
(SENT
  (S
    (NP-SBJ-1 (DT:[1259..1262] The) (NN:[1264..1272] mutation))
    (VP (VBD:[1273..1276] was) (RB:[1277..1280] not)
      (VP (VBN:[1281..1285] seen)
        (NP-1 (-NONE-:[1285..1285] *))
        (PP (IN:[1286..1288] in)
          (NP
            (NP (DT:[1289..1292] any))
            (PP (IN:[1293..1295] of)
              (NP
                (NP (CD:[1296..1298] 15) (NNS:[1299..1304] cases))
                (PP (IN:[1305..1307] of)
                  (NP
                    (ADJP (RB:[1308..1312] well) (HYPH:[1312..1313] -)
                          (VBN:[1313..1327] differentiated))
                    (NN:[1328..1339] liposarcoma)))))))))
    (.:[1339..1340] .))
  (S
    (NP-SBJ (NNS:[1342..1346] MFHs))
    (VP (VBD:[1347..1353] showed)
      (NP (DT:[1354..1356] an) (NN:[1357..1362] H-ras)
          (NN:[1363..1371] mutation))
      (PP (IN:[1372..1374] in)
        (NP
          (NP (CD:[1375..1376] 1)
            (PRN (-LRB-:[1377..1378] -LRB-)
              (NP (CD:[1378..1380] 12) (NN:[1380..1381] %))
              (-RRB-:[1381..1382] -RRB-)))
          (PP (IN:[1383..1385] of)
            (NP (CD:[1386..1387] 8) (NNS:[1388..1393] cases))))))
    (.:[1393..1394] .)))
;ERROR_Sentence has multiple Children (Sentence Error)[1259..1394]::S:S:

;section 11 Span:1395..1606
;Our results seem to suggest  that the H-ras mutation is a relatively uncommon
;event in dedifferentiated  liposarcoma, which may demonstrate an
;epiphenomenon of dedifferentiation in  dedifferentiated liposarcoma.
;[1433..1438]:gene-rna:"H-ras"
;[1482..1511]:malignancy:"dedifferentiated  liposarcoma"
;[1577..1605]:malignancy:"dedifferentiated liposarcoma"
(SEC
  (S
    (NP-SBJ-2 (PRP$:[1395..1398] Our) (NNS:[1399..1406] results))
    (VP (VBP:[1407..1411] seem)
      (S
        (NP-SBJ-2 (-NONE-:[1411..1411] *))
        (VP (TO:[1412..1414] to)
          (VP (VB:[1415..1422] suggest)
            (SBAR (IN:[1424..1428] that)
              (S
                (NP-SBJ (DT:[1429..1432] the) (NN:[1433..1438] H-ras)
                        (NN:[1439..1447] mutation))
                (VP (VBZ:[1448..1450] is)
                  (NP-PRD (DT:[1451..1452] a)
                    (ADJP (RB:[1453..1463] relatively)
                          (JJ:[1464..1472] uncommon))
                    (NN:[1473..1478] event))
                  (PP (IN:[1479..1481] in)
                    (NP (VBN:[1482..1498] dedifferentiated)
                        (NN:[1500..1511] liposarcoma)))
                  (,:[1511..1512] ,)
                  (SBAR-ADV
                    (WHNP-1 (WDT:[1513..1518] which))
                    (S
                      (NP-SBJ-1 (-NONE-:[1518..1518] *T*))
                      (VP (MD:[1519..1522] may)
                        (VP (VB:[1523..1534] demonstrate)
                          (NP
                            (NP (DT:[1535..1537] an)
                                (NN:[1538..1551] epiphenomenon))
                            (PP (IN:[1552..1554] of)
                              (NP (NN:[1555..1572] dedifferentiation))))
                          (PP (IN:[1573..1575] in)
                            (NP (VBN:[1577..1593] dedifferentiated)
                                (NN:[1594..1605] liposarcoma))))))))))))))
    (.:[1605..1606] .)))
;ERROR_Entity in section[1433..1438]:gene-rna "H-ras"
;ERROR_Entity in section[1482..1511]:malignancy "dedifferentiated 
;liposarcoma"
;ERROR_Entity in section[1577..1605]:malignancy "dedifferentiated
;liposarcoma"

;section 12 Span:1610..1655
;PMID: 11211612 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1610..1614] PMID) (::[1614..1615] :) (CD:[1616..1624] 11211612)
        (NN:[1625..1626] -LSB-) (NNP:[1626..1632] PubMed) (::[1633..1634] -)
        (NN:[1635..1642] indexed) (IN:[1643..1646] for)
        (NNP:[1647..1655] MEDLINE-RSB-)))
